Form 4: Akero Therapeutics Director, Jane Henderson, Reports Stock Option Grant

Jane Henderson, a director of Akero Therapeutics, Inc., reported the acquisition of stock options on June 8, 2024.

Summary

• On June 11, 2024, a Form 4 filing with the SEC revealed that Jane Henderson, a director at Akero Therapeutics, Inc. (AKRO), acquired stock options.
• The transaction occurred on June 8, 2024, granting Henderson the right to buy 26,000 shares of Akero Therapeutics common stock at an exercise price of $23.02 per share.
• These options vest fully on the earlier of June 7, 2025, or the next annual meeting of the company's stockholders, contingent upon continued service on the Board.
• Following this transaction, Henderson directly owns 26,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a routine disclosure of stock option grants, which is neither particularly positive nor negative. It's a standard part of executive compensation.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of directors and management with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The size of the grant (26,000 shares) would need to be compared against grants to directors at comparable companies like Viking Therapeutics or Madrigal Pharmaceuticals to assess its relative value.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with those of the shareholders.

Key Dates